Sutro Biopharma, Inc. (STRO) total debt
Sutro Biopharma, Inc. (STRO) carried total debt of $15.67M at the end of fiscal 2025 (December 31, 2025). That is 32.3% lower than the $23.15M of fiscal 2024. Figures as of 18 Nov 2026, 01:10 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Total debt, fiscal 2025
- $15.67M
- Change on fiscal 2024
- −32.3%
- Growth, 5 years
- −8.6% a year
- Highest on record
- $50.43Mfiscal 2022
- Lowest on record
- $9.88Mfiscal 2019
- Fiscal years on record
- 82018–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Sutro Biopharma, Inc. total debt, in more detail
Over the five fiscal years to 2025 total debt shrank at a compound 8.6% a year. Across the 8 fiscal years on record (2018–2025), the highest was $50.43M in fiscal 2022 and the lowest $9.88M in fiscal 2019.
Total debt by fiscal year
Sutro Biopharma, Inc. total debt, year by year
| Fiscal year | Total debt | Change | Year ended | Debt ÷ equity |
|---|---|---|---|---|
| 2025 | $15.67M | 32.3% down | — | |
| 2024 | $23.15M | 31.2% down | 0.5× | |
| 2023 | $33.64M | 33.3% down | 0.2× | |
| 2022 | $50.43M | 100.8% up | 0.2× | |
| 2021 | $25.11M | 2.3% up | 0.1× | |
| 2020 | $24.55M | 148.5% up | 0.1× | |
| 2019 | $9.88M | 32.9% down | 0.1× | |
| 2018 | $14.72M | — | 0.1× |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
How to read it
Debt magnifies results in both directions — set it against cash, equity and the profit available to pay the interest rather than reading it alone.
Sutro Biopharma, Inc., figure by figure
- Sutro Biopharma, Inc. market cap
- Sutro Biopharma, Inc. revenue
- Sutro Biopharma, Inc. earnings
- Sutro Biopharma, Inc. earnings per share (EPS)
- Sutro Biopharma, Inc. P/E ratio
- Sutro Biopharma, Inc. P/S ratio
- Sutro Biopharma, Inc. P/B ratio
- Sutro Biopharma, Inc. free cash flow
- Sutro Biopharma, Inc. operating margin
- Sutro Biopharma, Inc. dividend
- Sutro Biopharma, Inc. shares outstanding
- Sutro Biopharma, Inc. cash on hand
- Sutro Biopharma, Inc. total assets
- Sutro Biopharma, Inc. return on equity (ROE)
- Sutro Biopharma, Inc. return on invested capital (ROIC)
Sutro Biopharma, Inc. (STRO) overview: price, valuation and scorecard
Sutro Biopharma, Inc. total debt: questions and answers
How much debt does Sutro Biopharma, Inc. have?
Sutro Biopharma, Inc. (STRO) carried total debt of $15.67M at the end of fiscal 2025 (December 31, 2025). That is 32.3% lower than the $23.15M of fiscal 2024.
What is the growth rate of Sutro Biopharma, Inc.'s total debt?
Over the five fiscal years to 2025 total debt shrank at a compound 8.6% a year.
What are the highest and lowest total debt figures on record for Sutro Biopharma, Inc.?
Across the 8 fiscal years on record (2018–2025), the highest was $50.43M in fiscal 2022 and the lowest $9.88M in fiscal 2019.
How is Sutro Biopharma, Inc.'s total debt calculated?
Total debt adds the short-term and long-term borrowings on the balance sheet at the fiscal year-end; debt-to-equity divides it by shareholders' equity and is left blank when equity is negative.
Fiscal years are named for the calendar year they end in.
Learn: total debt
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Sutro Biopharma, Inc. (STRO) total debt”, data as of 18 November 2026. https://funkfolio.com/stock/STRO/total-debt
Underlying data: the company's filings with the SEC and Yahoo Finance.